Estabrook Capital Management cut its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 17.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 296,030 shares of the biopharmaceutical company's stock after selling 64,456 shares during the quarter. Pfizer makes up about 1.2% of Estabrook Capital Management's holdings, making the stock its 22nd biggest position. Estabrook Capital Management's holdings in Pfizer were worth $7,854,000 at the end of the most recent reporting period.
Other institutional investors have also added to or reduced their stakes in the company. Retirement Wealth Solutions LLC bought a new position in shares of Pfizer in the fourth quarter valued at approximately $26,000. Rialto Wealth Management LLC bought a new position in Pfizer in the 4th quarter valued at $26,000. Kohmann Bosshard Financial Services LLC purchased a new stake in shares of Pfizer during the 4th quarter valued at $28,000. Noble Wealth Management PBC bought a new stake in shares of Pfizer during the 4th quarter worth $31,000. Finally, Curio Wealth LLC purchased a new position in shares of Pfizer in the 4th quarter worth about $32,000. 68.36% of the stock is owned by institutional investors.
Pfizer Price Performance
NYSE:PFE traded up $0.30 during mid-day trading on Friday, hitting $21.89. 55,013,451 shares of the stock traded hands, compared to its average volume of 40,232,439. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The company has a market cap of $124.14 billion, a PE ratio of 15.52, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67. The business's 50-day moving average price is $25.25 and its 200 day moving average price is $26.38.
Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. The firm had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business's revenue for the quarter was up 24.7% on a year-over-year basis. During the same period in the previous year, the business earned $0.10 EPS. On average, analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.
Insider Buying and Selling at Pfizer
In related news, Director Ronald E. Blaylock acquired 19,457 shares of the firm's stock in a transaction that occurred on Thursday, February 13th. The shares were bought at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the transaction, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.06% of the company's stock.
Analyst Ratings Changes
A number of analysts recently issued reports on the stock. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a report on Monday, March 10th. The Goldman Sachs Group restated a "neutral" rating and set a $25.00 price target (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Truist Financial dropped their price objective on Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a research note on Wednesday, December 18th. UBS Group decreased their target price on Pfizer from $28.00 to $24.00 and set a "neutral" rating for the company in a research report on Tuesday, April 8th. Finally, Citigroup restated a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $31.07.
Check Out Our Latest Stock Analysis on Pfizer
Pfizer Profile
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Further Reading
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
